Global Health and Lincoln Park team up
This article was originally published in The Tan Sheet
Specialty pharmaceutical firm Global Health Ventures signs an equity purchase agreement with Lincoln Park Capital Fund for up to $20 million, the Canadian maker of sublingually delivered lifestyle products said May 28. Global Health says it has the right to sell shares of common stock to the Chicago-based institutional investor over a 30-month period in amounts between $100,000 and $1 million, and up to the $20 million limit depending on conditions of the agreement. Global Health says the finance proceeds will help it develop the male enhancement drug X-Excite and other drugs, license new products and acquire other companies
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
COVID-19 has not held back GSK's preparations to create the world's largest standalone consumer health business, with CEO Emma Walmsley confirming separation is on track for summer next year.